Clinical Trial

Gyrate Atrophy Ocular and Systemic Study

Study acronym: GYROS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT mutations on plasma ornithine levels and retinal degeneration. Funding Source- FDA OOPD
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2022-03-28; most recent amendment 2026-01-22.
Status change: Recruiting → Active, Not Recruiting 2025-02-21
Status change: Not Yet Recruiting → Recruiting 2023-11-28
Trial Details
NCT Number NCT05312736
Lead Sponsor Jaeb Center for Health Research
Collaborators: Conquering Gyrate Atrophy Foundation, Foundation Fighting Blindness
Conditions Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration
Enrollment 46 participants
Start Date 2023-11-21
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-26